Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer

被引:65
作者
Tempfer, C
Losch, A
Heinzl, H
Hausler, G
Hanzal, E
Kolbl, H
Breitenecker, G
Kainz, C
机构
[1] UNIV VIENNA,SCH MED,DEPT MED COMP SCI,A-1090 VIENNA,AUSTRIA
[2] UNIV VIENNA,SCH MED,DEPT GYNAECOPATHOL,A-1090 VIENNA,AUSTRIA
关键词
breast; neoplasm; adhesion molecules; prognosis;
D O I
10.1016/0959-8049(96)00185-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the expression of CD44 isoforms containing variant exons v5, v6 and v7-8 in 115 human breast cancer specimens by means of immunohistochemistry. CD44 isoforms CD44v5, CD44v6 and CD44v7-8 were detected in 56% (n = 64), 24% (n = 28) and 15% (n = 17), respectively. In 36 specimens of axillary lymph node metastasis, expression of CD44v5, CD44v6 and CD44v7-8 was found in 94% (n = 34), 92% (n = 33) and 89% (n = 32), respectively. Five year survival rates with or without CD44v5 and CD44v6 expression were 71% versus 86% (log-rank test, P = 0.02) and 62% versus 81% (log-rank test, P = 0.001), respectively. For disease-free survival, expression of CD44v5, CD44v6 and CD44v7-8 showed a prognostic impact (log-rank test, P = 0.004, P = 0.0001 and P = 0.0001, respectively). However, multivariate analysis revealed that all investigated CD44 isoforms failed to be independent predictors of the patient's outcome. Copyright (C) 1996 Elsevier Science Ltd
引用
收藏
页码:2023 / 2025
页数:3
相关论文
共 12 条
  • [1] PARTICIPATION IN NORMAL IMMUNE-RESPONSES OF A METASTASIS-INDUCING SPLICE VARIANT OF CD44
    ARCH, R
    WIRTH, K
    HOFMANN, M
    PONTA, H
    MATZKU, S
    HERRLICH, P
    ZOLLER, M
    [J]. SCIENCE, 1992, 257 (5070) : 682 - 685
  • [2] CAVALCANTI GB, 1994, BRAZ J MED BIOL RES, V27, P2259
  • [3] PREFERENTIAL EXPRESSION OF THE CELL-ADHESION MOLECULE CD44 IN PAPILLARY THYROID-CARCINOMA
    FIGGE, J
    DELROSARIO, AD
    GERASIMOV, G
    DEDOV, I
    BRONSTEIN, M
    TROSHINA, K
    ALEXANDROVA, G
    KALLAKURY, BVS
    BUI, HX
    BRATSLAVSKY, G
    ROSS, JS
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 1994, 61 (03) : 203 - 211
  • [4] HERMANEK P, 1992, UICC TNM CLASSIFICAT
  • [5] CD44 SPLICE VARIANTS - METASTASES MEET LYMPHOCYTES
    HERRLICH, P
    ZOLLER, M
    PALS, ST
    PONTA, H
    [J]. IMMUNOLOGY TODAY, 1993, 14 (08): : 395 - 399
  • [6] LYMPHOCYTE HOMING AND CLINICAL BEHAVIOR OF NON-HODGKINS-LYMPHOMA
    JALKANEN, S
    JOENSUU, H
    SODERSTROM, KO
    KLEMI, P
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (05) : 1835 - 1840
  • [7] JOENSUU H, 1993, AM J PATHOL, V143, P867
  • [8] LYMPHOCYTE HOMING RECEPTOR (CD44) EXPRESSION IS ASSOCIATED WITH POOR-PROGNOSIS IN GASTROINTESTINAL LYMPHOMA
    JOENSUU, H
    RISTAMAKI, R
    KLEMI, PJ
    JALKANEN, S
    [J]. BRITISH JOURNAL OF CANCER, 1993, 68 (02) : 428 - 432
  • [9] SPLICE VARIANTS OF CD44 IN HUMAN CERVICAL-CANCER STAGE IB TO IIB
    KAINZ, C
    KOHLBERGER, P
    SLIUTZ, G
    TEMPFER, C
    HEINZL, H
    REINTHALLER, A
    BREITENECKER, G
    KOELBL, H
    [J]. GYNECOLOGIC ONCOLOGY, 1995, 57 (03) : 383 - 387
  • [10] CD44 VARIANT EXON EPITOPES IN PRIMARY BREAST-CANCER AND LENGTH OF SURVIVAL
    KAUFMANN, M
    HEIDER, KH
    SINN, HP
    VONMINCKWITZ, G
    PONTA, H
    HERRLICH, P
    [J]. LANCET, 1995, 345 (8950): : 615 - 619